［1］Siegel R，Naishadham D，Jemal A.Cancer statistics，2012［J］.CA Cancer J Clin，2012，62(1)：10-29.
［2］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China［J］.CA Cancer J Clin，2016，66（2)：115－132．
［3］Jemal A，Siegel R，Xu J，et al.Cancer statistics，2010［J］.CA Cancer J Clin，2010，60(5)：277-300.
［4］Shen J，He WX.The short-term effect of docetaxel combined with cisplatin in the treatment of non-small cell lung cancer［J］.Journal of Chinese Practical Diagnosis and Therapy，2012，26(1)：68-69.［申洁，贺外信．多西他赛联合顺铂治疗非小细胞肺癌近期疗效观察［J］.中华实用诊断与治疗杂志，2012，26（1）：68-69.］
［5］Burotto M，Manasanch EE，Wilkerson J，et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer：A Meta-analysis of toxicity and efficacy of randomized clinical trials［J］.Oncologist，2015，20(4)：400-410.
［6］Eisenhauer EA，Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours：Revised RECIST guideline(version 1.1)［J］.Eur J Cancer，2009，45(2)：228-247.
［7］Sun Y，Shi YK.Manual of medical oncology［M］.Beijing：People's Health Publishing House，2015：Appendix 1-6.［孙燕，石远凯.临床肿瘤内科手册［M］.北京：人民卫生出版社，2015：附录1-6.］
［8］Zhuang J，Yu Y，Li Z，et al.Efficacy of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation：A pooled analysis［J］.Oncotarget，2017，8(32)：53675-53683.
［9］Lee KE，Hahm E，Bae，et al.The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells［J］.Oncol Lett，2017，14(1)：276-282.
［10］Mokt S，Wu YL，Thongpaserts S，et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma［J］.N Engl J Med，2009，361(10)：947-957.
［11］Wu YL，Saijo N，Thonqprasert S，et al.Efficacy according to blind independent central review：Post-hoc analyses from the phase Ⅲ，randomized，multicenter，IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC［J］.Lung Cancer，2017，104(2)119-125.
［12］Wu F，Zhang S，Gao G，et al.Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer：A case report and literature review［J］.Cancer Biol Ther，2018，19(3)：141-144.
［13］Karayama M，Inui N，Fujisawa T，et al．Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin，pemetrexed，and bevacizumab in patients with advanced non-squamous non small cell lung cancer［J］．Eur J Cancer，2016，58(6)：30－37．
［14］Li JY，Wu XM，He LH，et al.Efficacy of EGFR-TKI and chemotherapy in advanced non-small cell lung cancer with EGFR-TKI resistence［J］.China Oncology，2013，23(6)：462-466.［李剑英，吴晓敏，何灵慧.EGFR-TKI联合化疗治疗EGFRTKI获得性耐药的晚期非小细胞肺癌疗效分析［J］.中国癌症杂志，2013，23(6)：462-466.］
［15］Ding T，Zhou F，Chen X，et al.Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations［J］.J Thorac Dis，2017，9(9)：2923-2934.
［16］Goldberg SB，Oxnard GR，Digumarthy S，et al.Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors［J］.Oncologist，2013，18(11)：1214-1220.